Affiliation:
1. Department of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha 410011, China
2. Clinical Medical Research Center for Systemic Autoimmune Diseases in Hunan Province, Changsha 410011, China
Abstract
The constant updating of lupus drug treatment guidelines has led to a question. How can the efficacy of treatment be more effectively monitored? Systemic lupus erythematosus (SLE) is a complex autoimmune disease that often presents clinically with multi-organ involvement, and approximately 30% of patients with SLE develop lupus nephritis (LN). Therefore, it is important to better track disease progression and drug efficacy. Now, kidney biopsy is still the gold standard for diagnosing and guiding the treatment of LN, but it is invasive and expensive. If simple, non-invasive and effective biomarkers can be found, drug intervention and prognosis can be better monitored and targeted. In this review, we focus on LN and explore biomarkers related to LN therapeutics, providing clinicians with more possibilities to track the therapeutic effect of drugs, improve treatment options and assess patient outcomes.
Subject
Molecular Biology,Biochemistry
Reference82 articles.
1. Lupus nephritis: New progress in diagnosis and treatment;Yu;J. Autoimmune,2022
2. Risk and Factors associated with disease manifestations in systemic lupus erythematosus—Lupus nephritis (RIFLE-LN): A ten-year risk prediction strategy derived from a cohort of 1652 patients;Chan;Front. Immunol.,2023
3. Ahmad, A., Imran, M., and Ahsan, H. (2023). Biomarkers as Biomedical Bioindicators: Approaches and Techniques for the Detection, Analysis, and Validation of Novel Biomarkers of Diseases. Pharmaceutics, 15.
4. The immune cell landscape in kidneys of patients with lupus nephritis;Arazi;Nat. Immunol.,2019
5. Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis;Pollak;J. Lab. Clin. Med.,1961